Search

Your search keyword '"Antineoplastic agents -- Marketing"' showing total 4 results
Start Over Descriptor "Antineoplastic agents -- Marketing" Journal aids weekly
4 results on '"Antineoplastic agents -- Marketing"'

1. Liposome Technology Inc. seeks U.S. marketing for DOX-SL

Subjects
Liposome Technology Inc. -- Marketing, Antineoplastic agents -- Marketing, Kaposi's sarcoma
Abstract

Industry News Liposome Technology Inc. (LTI), Menlo Park, California, announced that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its proprietary [...]

Published
1994

2. Caelyx launch announced in United Kingdom and Germany to treat tumors

Subjects
Tumors, Antineoplastic agents -- Marketing
Abstract

Sequus Pharmaceuticals, Inc., Menlo Park, California, announced that Schering-Plough Corp. has initiated the sales of Caelyx (doxorubicin HCl [pegylated liposomal]) in the United Kingdom and Germany. Sequus and Schering-Plough have [...]

Published
1997

3. Russia approves AmBisome and DaunoXome

Subjects
NeXstar Pharmaceuticals Inc. -- International trade, AmBisome (Medication) -- Marketing, DaunoXome (Medication) -- Marketing, Antifungal agents -- Marketing, Antineoplastic agents -- Marketing
Abstract

NeXstar Pharmaceuticals, Inc., Boulder, Colorado, announced that the Russian Ministry of Health granted marketing approval for its two proprietary liposomal products, AmBisome and DaunoXome. The Russian Ministry of Health approved [...]

Published
1997

4. France approves DaunoXome to treat KS

Subjects
Kaposi's sarcoma, Antineoplastic agents -- Marketing
Abstract

NeXstar Pharmaceuticals Inc., Boulder, Colorado, announced that the French Ministry of Health has approved DaunoXome as primary therapy for advanced AIDS related Kaposi's sarcoma (KS) in severely immuno-compromised patients with [...]

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results